96 related articles for article (PubMed ID: 32615661)
1. Rational Design of Hypoallergenic Vaccines: Blocking IgE-binding to Polcalcin Using Allergen-specific IgG Antibodies.
Mohammadi M; Khamisipour G; Soltanpour F; Omrani F; Taheri B; Momenzadeh N; Fouladvand M
Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):276-288. PubMed ID: 32615661
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of a hypoallergenic peptide-based vaccine for Salsola kali allergy.
Tabesh S; Fanuel S; Fazlollahi MR; Yekaninejad MS; Kardar GA; Razavi SA
Int Immunopharmacol; 2019 Jan; 66():62-68. PubMed ID: 30445308
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of Chenopodium album allergy with a cocktail of recombinant allergens as a tool for component-resolved diagnosis.
Nouri HR; Sankian M; Vahedi F; Afsharzadeh D; Rouzbeh L; Moghadam M; Varasteh A
Mol Biol Rep; 2012 Mar; 39(3):3169-78. PubMed ID: 21713408
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.
Sani MZ; Bargahi A; Momenzadeh N; Dehghani P; Moghadam MV; Maleki SJ; Nabipour I; Shirkani A; Akhtari J; Hesamizadeh K; Heidari S; Omrani F; Akbarzadeh S; Mohammadi M
Appl Microbiol Biotechnol; 2021 Jan; 105(1):77-91. PubMed ID: 33215260
[TBL] [Abstract][Full Text] [Related]
6. Enhanced sublingual immunotherapy by TAT-fused recombinant allergen in a murine rhinitis model.
Salari F; Vahedi F; Varasteh AR; Ketabdar H; Chamani J; Sankian M
Int Immunopharmacol; 2017 Jul; 48():118-125. PubMed ID: 28501765
[TBL] [Abstract][Full Text] [Related]
7. Ole e 3, a Candidate for in vivo Diagnosis of Polcalcin Sensitization.
Moya R; González-Ruiz A; Beitia JM; Carnés J; López-Matas MÁ
Int Arch Allergy Immunol; 2021; 182(6):465-473. PubMed ID: 33461195
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of T-cell epitopes from tetanus and diphtheria toxoids into in-silico-designed hypoallergenic vaccine may enhance the protective immune response against allergens.
Ghasemi A; Falak R; Mohammadi M; June Maleki S; Assarezadegan MA; Jafary M
Iran J Basic Med Sci; 2020 May; 23(5):636-644. PubMed ID: 32742602
[TBL] [Abstract][Full Text] [Related]
9. Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy.
Twaroch TE; Focke M; Civaj V; Weber M; Balic N; Mari A; Ferrara R; Quirce S; Spitzauer S; Swoboda I; Valenta R
J Allergy Clin Immunol; 2011 Jul; 128(1):178-184.e7. PubMed ID: 21513971
[TBL] [Abstract][Full Text] [Related]
10. Cloning and expression of Che a 1, the major allergen of Chenopodium album in Escherichia coli.
Vahedi F; Sankian M; Moghadam M; Mohaddesfar M; Ghobadi S; Varasteh AR
Appl Biochem Biotechnol; 2011 Apr; 163(7):895-905. PubMed ID: 20872185
[TBL] [Abstract][Full Text] [Related]
11. Epitope Mapping of Rhi o 1 and Generation of a Hypoallergenic Variant: A CANDIDATE MOLECULE FOR FUNGAL ALLERGY VACCINES.
Sircar G; Jana K; Dasgupta A; Saha S; Gupta Bhattacharya S
J Biol Chem; 2016 Aug; 291(34):18016-29. PubMed ID: 27358405
[TBL] [Abstract][Full Text] [Related]
12. Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.
Gadermaier E; Marth K; Lupinek C; Campana R; Hofer G; Blatt K; Smiljkovic D; Roder U; Focke-Tejkl M; Vrtala S; Keller W; Valent P; Valenta R; Flicker S
Allergy; 2018 Jul; 73(7):1425-1435. PubMed ID: 29315611
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional structure of the cross-reactive pollen allergen Che a 3: visualizing cross-reactivity on the molecular surfaces of weed, grass, and tree pollen allergens.
Verdino P; Barderas R; Villalba M; Westritschnig K; Valenta R; Rodriguez R; Keller W
J Immunol; 2008 Feb; 180(4):2313-21. PubMed ID: 18250440
[TBL] [Abstract][Full Text] [Related]
14. Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination.
Ball T; Linhart B; Sonneck K; Blatt K; Herrmann H; Valent P; Stoecklinger A; Lupinek C; Thalhamer J; Fedorov AA; Almo SC; Valenta R
Allergy; 2009 Apr; 64(4):569-80. PubMed ID: 19243361
[TBL] [Abstract][Full Text] [Related]
15. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.
Linhart B; Focke-Tejkl M; Weber M; Narayanan M; Neubauer A; Mayrhofer H; Blatt K; Lupinek C; Valent P; Valenta R
J Immunol; 2015 Apr; 194(8):4008-18. PubMed ID: 25786690
[TBL] [Abstract][Full Text] [Related]
16. Rational design of a hypoallergenic Phl p 7 variant for immunotherapy of polcalcin-sensitized patients.
Raith M; Zach D; Sonnleitner L; Woroszylo K; Focke-Tejkl M; Wank H; Graf T; Kuehn A; Pascal M; Muñoz-Cano RM; Wortmann J; Aschauer P; Keller W; Braeuer S; Goessler W; Swoboda I
Sci Rep; 2019 May; 9(1):7802. PubMed ID: 31127132
[TBL] [Abstract][Full Text] [Related]
17. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
18. Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.
Curin M; Weber M; Thalhamer T; Swoboda I; Focke-Tejkl M; Blatt K; Valent P; Marth K; Garmatiuk T; Grönlund H; Thalhamer J; Spitzauer S; Valenta R
Clin Exp Allergy; 2014 Jun; 44(6):882-94. PubMed ID: 24552249
[TBL] [Abstract][Full Text] [Related]
19. Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy.
Freidl R; Gstoettner A; Baranyi U; Swoboda I; Stolz F; Focke-Tejkl M; Wekerle T; van Ree R; Valenta R; Linhart B
J Allergy Clin Immunol; 2017 Jun; 139(6):1897-1905.e1. PubMed ID: 27876628
[TBL] [Abstract][Full Text] [Related]
20. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
